Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Polyzois Makras

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Archives of Osteoporosis|June 27, 2022
Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in GreeceMaria P Yavropoulou, Polyzois Makras, Kostas Athanasakis, et al.
Journal of Musculoskeletal & Neuronal Interactions|September 3, 2019
Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone massAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 15, 2016
Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case SeriesDeepak Chellapandian, Polyzois Makras, Gregory Kaltsas, et al.
The Journal of Clinical Endocrinology and Metabolism|May 12, 2021
The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its DiscontinuationPolyzois Makras, Natasha M Appelman-Dijkstra, Socrates E Papapoulos, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 23, 2026
Alendronate for 6 or 12 months following denosumab discontinuation in women with postmenopausal osteoporosis: A prospective observational studyPolyzois Makras, Athanasios D Anastasilakis, Andrea Palermo, et al.
Maturitas|November 17, 2023
Nocebo-associated treatment discontinuation with subcutaneous anti-osteoporotic drugs. A systematic review and meta-analysis of placebo-arm dropouts in randomized-controlled trialsMaria P Yavropoulou, Maria-Iosifina Kasdagli, Polyzois Makras, et al.
Archives of Osteoporosis|March 17, 2019
The 2018 Guidelines for the diagnosis and treatment of osteoporosis in GreecePolyzois Makras, Athanasios D Anastasilakis, George Antypas, et al.
JBMR Plus|February 22, 2021
Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid AdenomasMaria P Yavropoulou, Kalliopi Pazaitou-Panayiotou, John G Yovos, et al.
Bone|February 28, 2012
Acute phase response following intravenous zoledronate in postmenopausal women with low bone massAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Metabolism: Clinical and Experimental|June 29, 2013
Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literatureAthanasios D Anastasilakis, Rosaria-Maddalena Ruggeri, Stergios A Polyzos, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Archives of Osteoporosis|June 27, 2022
Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in GreeceMaria P Yavropoulou, Polyzois Makras, Kostas Athanasakis, et al.
Journal of Musculoskeletal & Neuronal Interactions|September 3, 2019
Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone massAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 15, 2016
Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case SeriesDeepak Chellapandian, Polyzois Makras, Gregory Kaltsas, et al.
The Journal of Clinical Endocrinology and Metabolism|May 12, 2021
The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its DiscontinuationPolyzois Makras, Natasha M Appelman-Dijkstra, Socrates E Papapoulos, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 23, 2026
Alendronate for 6 or 12 months following denosumab discontinuation in women with postmenopausal osteoporosis: A prospective observational studyPolyzois Makras, Athanasios D Anastasilakis, Andrea Palermo, et al.
Maturitas|November 17, 2023
Nocebo-associated treatment discontinuation with subcutaneous anti-osteoporotic drugs. A systematic review and meta-analysis of placebo-arm dropouts in randomized-controlled trialsMaria P Yavropoulou, Maria-Iosifina Kasdagli, Polyzois Makras, et al.
Archives of Osteoporosis|March 17, 2019
The 2018 Guidelines for the diagnosis and treatment of osteoporosis in GreecePolyzois Makras, Athanasios D Anastasilakis, George Antypas, et al.
JBMR Plus|February 22, 2021
Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid AdenomasMaria P Yavropoulou, Kalliopi Pazaitou-Panayiotou, John G Yovos, et al.
Bone|February 28, 2012
Acute phase response following intravenous zoledronate in postmenopausal women with low bone massAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Metabolism: Clinical and Experimental|June 29, 2013
Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literatureAthanasios D Anastasilakis, Rosaria-Maddalena Ruggeri, Stergios A Polyzos, et al.
Pageof 13